title: [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
authors.forename: C
authors.initials: C
authors.lastname: Warnke
authors.forename: O
authors.initials: O
authors.lastname: Adams
authors.forename: H P
authors.initials: HP
authors.lastname: Hartung
authors.forename: R
authors.initials: R
authors.lastname: Gold
authors.forename: B
authors.initials: B
authors.lastname: Hemmer
authors.forename: R
authors.initials: R
authors.lastname: Hohlfeld
authors.forename: M
authors.initials: M
authors.lastname: Stangel
authors.forename: F
authors.initials: F
authors.lastname: Zipp
authors.forename: H
authors.initials: H
authors.lastname: Wiendl
authors.forename: B C
authors.initials: BC
authors.lastname: Kieseier
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000097:blood*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007577:JC Virus / Q000276:immunology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D008134:Long-Term Care; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D007166:Immunosuppressive Agents; D000069442:Natalizumab